Bevacizumab in recurrent high-grade pediatric gliomas
نویسندگان
چکیده
منابع مشابه
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
PURPOSE Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade ...
متن کاملCirculating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
2044 Background: Bevacizumab (Bev), a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), has shown significant activity in a subset of patients with high grade gliomas (HGG): to date no biological marker can predict the treatment benefit. Circulating endothelial cells (CEC) and progenitors (CEP) have been observed in cancer patients, reflecting ongoing tumor angiogenes...
متن کاملMR perfusions imaging of anti angiogenic (bevacizumab) treatment in patients with recurrent high grade gliomas
Introduction: Perfusion MRI has become a powerful tool for evaluating brain tumors (1). Anti-angiogenic therapy using bevacizumab (Avastin) affects abnormal neovascularity which is a hallmark of high grade primary brain tumors. Alterations in neovascularity result in hemodynamic changes; therefore, perfusion imaging would be an ideal surrogate for assessing the effects of anti-angiogenic therap...
متن کاملFDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Prognosis of recurrent high-grade glioma (HGG) is poor, although bevacizumab has been documented in that context. This study aimed to determine the independent prognostic value of fluorodeoxyglucose (FDG)-PET on progression-free survival (PFS) and overall survival (OS) of recurrent HGG after combined treatment with bevacizumab and irinotecan, compared with other documented prognostic variables....
متن کاملTreatment of recurrent high-grade gliomas.
PURPOSE OF REVIEW Although therapies for patients with recurrent high-grade gliomas are limited, there has been important progress recently. This review summarizes current treatments for recurrent high-grade gliomas with an emphasis on more novel approaches. RECENT FINDINGS There is increasing evidence that antiangiogenic therapies have activity in high-grade gliomas. Recently, the United Sta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2010
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noq033